PSA remains best indicator of prostate cancer progression

09/12/05

Despite recent claims by some urologists that measuring the blood protein
prostate-specific antigen (PSA) may not be effective in predicting risk of
prostate cancer, a Johns Hopkins study of more than 2,000 men confirms that
PSA remains the best measure of the likelihood of cancer recurrence after
surgery.

Results of the study, published in the October issue of The Journal of
Urology, demonstrated that men with high PSA levels prior to prostate
removal surgery were significantly more likely to have advanced clinical
stages of cancer, evidence of higher grade cancers in surgically removed
tissue, and spread of cancer cells beyond the prostate. In addition,
increasing PSA was significantly associated with increased risk of cancer
recurrence after surgery, even in men with lower PSA levels prior to surgery.

The study was led by Stephen J. Freedland, M.D., clinical instructor of
urology, and Alan W. Partin, M.D., Ph.D., professor and chair of urology at
Johns Hopkins' Brady Urological Institute.

"In our study, PSA levels measured before prostate removal surgery were
significantly associated with the risk of recurrent cancer after surgery,"
Freedland says. "These data support the notion that PSA remains the best
available prostate cancer tumor marker. It certainly suggests that the PSA
era is alive and well."

PSA is a protein produced by cells of the prostate gland. Prostate cancer
can increase PSA, so the higher the PSA level, the greater the likelihood
that a patient has prostate cancer. Also, higher PSA values generally
reflect larger, more aggressive cancers. Freedland acknowledges that
because PSA provides physicians with a measure of a patient's prostate
health at a single point in time, it's "far from perfect." However, he
says, "it's better than anything else we have."

"As a screening tool, PSA has done what we wanted it to do," Freedland
says. "It detects advanced disease early and reduces the likelihood of
metastatic disease."

For the study, Freedland and colleagues reviewed patient records for 2,312
men who had prostate removal surgery at Johns Hopkins between 1992 and
2004. All operations were performed by Patrick C. Walsh, M.D., professor
and former chair of urology. The research team compared the association
between preoperative PSA and the risk of cancer recurrence after surgery.

During an average follow-up of five years, 211 men (10 percent) had signs
of recurrent cancer. Higher PSA levels prior to surgery were significantly
associated with increased risk of cancer after surgery. Compared to men
with PSA levels less than 10 nanograms per milliliter, men with PSA values
between 10 and 19.9 nanograms per milliliter were more than three times
more likely to develop cancer after surgery. Men with PSA levels of 20
nanograms per milliliter or greater were more than five times more likely
to develop cancer after surgery than those with low PSA levels.

Even in men with PSA values of less than 10 nanograms per milliliter,
increasing PSA was significantly associated with increased risk of cancer
after surgery. For each two-point increase in PSA, the risk of cancer after
surgery approximately doubled.

"From our study and others, it is clear that a single PSA value is an
extremely useful measure of a patient's risk of progression after surgery,"
Freedland says. "However, looking at how quickly the PSA increases over
time is likely to be even more informative than a single value."

Source: Eurekalert & others

Last reviewed:
By John M. Grohol, Psy.D. on
21 Feb 2009
Published on PsychCentral.com. All rights reserved.

Respect ... is appreciation of the separateness of the other person, of the ways in which he or she is unique. -- Annie Gottlier